Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SARCLISA vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor,Treatment of multiple myeloma in combination with carfilzomib and dexamethasone in adults with relapsed or refractory multiple myeloma after 1-3 prior lines of therapy
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Isatuximab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via catabolic pathways. Not metabolized by CYP450 enzymes.
Metabolized by exonucleases to shorter oligonucleotides.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
~70% bound to plasma proteins (primarily albumin and beta-2 glycoprotein I/apoferritin).
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Vd: 0.09 L/kg (approx. 6 L), consistent with limited extravascular distribution.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
IV only; bioavailability 100% by IV route. Not administered orally.
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment required for renal impairment (Cr Cl ≥15 m L/min). Not studied in end-stage renal disease (Cr Cl <15 m L/min) or dialysis; use caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Safety and efficacy not established in pediatric patients. No recommended dose.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment required. Consider comorbidities and renal function, but pharmacokinetics are similar to younger adults.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
No FDA black box warning.
None.
Infusion-related reactions (may require premedication and monitoring),Neutropenia (monitor complete blood counts),Thrombocytopenia,Second primary malignancies,Interference with blood cross-matching (due to CD38 binding),Embryofetal toxicity
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
None known.
Hypersensitivity to oblimersen or any component of the formulation
No specific food interactions. Avoid grapefruit juice if taking concurrent CYP3A4 substrates (e.g., pomalidomide) due to potential interaction. Maintain adequate hydration.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
First trimester: Ig G1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/third trimesters: Increased placental transfer; risk of fetal cytopenias and immune suppression.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
No data on human milk excretion; M/P ratio unknown. Human Ig G enters breast milk, but degradation in infant GI tract likely limits absorption. Weigh benefits of breastfeeding against potential infant exposure.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No PK studies in pregnancy; dose adjustments not established. Isatuximab clearance may increase due to expanded plasma volume and altered Fc Rn activity, but no data to recommend specific changes. Use only if benefit outweighs risk.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
SARCLISA (isatuximab) is an anti-CD38 monoclonal antibody for multiple myeloma. Premedicate with acetaminophen, H1 and H2 antagonists, and corticosteroids before infusion to reduce infusion-related reactions. Administer pomalidomide and dexamethasone concurrently as per protocol. Monitor for neutropenia, infusion reactions, and second primary malignancies. Do not substitute for other anti-CD38 antibodies.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
Infusion reactions: symptoms like fever, chills, rash, or difficulty breathing may occur during or after infusion; seek immediate medical attention.,Blood cell counts: this drug can decrease white blood cells, red blood cells, and platelets; report signs of infection, anemia, or bleeding.,Fetal harm: effective contraception required during and for 5 months after treatment; do not breastfeed.,Vaccinations: avoid live vaccines during treatment.,Laboratory interference: isatuximab may interfere with blood compatibility testing; inform all healthcare providers of treatment.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SARCLISA vs ANTHIM, answered by our medical review team.
SARCLISA is a Monoclonal Antibody, Antineoplastic that works by Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SARCLISA and ANTHIM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SARCLISA is: 10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SARCLISA and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SARCLISA is classified as Category C. First trimester: IgG1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/thir. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.